Crizanlizumab: First Approval

Area of Science:

• Hematology
• Immunology
• Pharmacology

Background:

• Sickle cell disease (SCD) is a genetic blood disorder characterized by vaso-occlusive crises (VOCs).
• P-selectin plays a crucial role in the pathophysiology of VOCs by mediating cellular adhesion.
• Existing treatments for SCD focus on managing symptoms and preventing complications.

Purpose of the Study:

• To summarize the development milestones of crizanlizumab.
• To highlight the regulatory approval of crizanlizumab for preventing VOCs in sickle cell disease.

Main Methods:

• Crizanlizumab is a monoclonal antibody that targets P-selectin.
• It blocks the interaction between P-selectin and its ligand, P-selectin glycoprotein ligand-1.
• Development involved preclinical studies and clinical trials to assess efficacy and safety.

Main Results:

• Crizanlizumab received FDA approval in November 2019 for reducing VOC frequency in SCD patients (≥16 years).
• The drug is under regulatory review in the EU for the same indication.
• Investigational use in myelofibrosis with ruxolitinib is also being explored.

Conclusions:

• Crizanlizumab represents a significant advancement in the management of sickle cell disease.
• Its approval marks a milestone in targeted therapy for preventing VOCs.
• Further research is ongoing for other indications and patient populations.